BioSpace News Archive

Avivagen Inc. (TSXV:VIV, OTCQB:VIVXF) (“Avivagen” or the “Corporation”) announces that a total of 3,931 common shares will be issued at the rate of $0.58 per share to satisfy the maintenance fee of $2,280 owing in respect of the debentures issued on April 9, 2019.

IRADIMED CORPORATION announced that the Company will release its 2021 first quarter financial results before the market opens on Friday, April 30th.

Bausch Health Companies Inc. will release its first-quarter 2021 financial results on Tuesday, May 4, 2021. Bausch Health will host a conference call and live web cast at 8:00 a.m. EDT to discuss the results and provide a business update.

Frequency Therapeutics, Inc., a clinical-stage biotechnology company focused on harnessing the body’s innate biology to repair or reverse damage caused by a broad range of degenerative diseases, announced that Chief Executive Officer David L. Lucchino will present a company overview at the 20th Annual Needham Virtual Healthcare Conference.

Phase 1 dose escalation and bioimaging study shows that ifabotuzumab demonstrates highly specific tumor targeting in patients with recurrent glioblastoma multiforme

Invitation to attend Vitrolife’s conference call regarding presentation of the interim report January - March 2021 . The presentation will be held in English. Time: Thursday 22 April, 2021 at 10.00 a.m. CET . Registration can preferably be done 10-15 minutes before the conference start time on: Sweden dial in number: +

CureVac N.V. (Nasdaq:CVAC), a biopharmaceutical company developing a new class of transformative medicines based on messenger ribonucleic acid will report financial results and business updates for the fourth quarter and Full-Year of 2020 on Thursday, April 15, 2021.

- First study evaluating CAR-macrophages in fully immunocompetent solid tumor mouse models shows significant tumor control, increased survival, and induction of anti-tumor immunity - New ultra-rapid, same-day CAR-monocyte manufacturing process may reduce “vein-to-vein” time

The American Society of Nephrology and the National Kidney Foundation announce the concurrent publication of “Special Article: Reassessing the Inclusion of Race in Diagnosing Kidney Diseases: An Interim Report from the NKF-ASN Task Force” in the Journal of the American Society of Nephrology and the American Journal of Kidney Diseases.

Schrödinger (Nasdaq: SDGR), whose physics-based software platform is transforming the way therapeutics and materials are discovered, today announced that Ramy Farid, Ph.D., chief executive officer at Schrödinger, will participate in a panel during the BMO BioPharma Spotlight Series: Technology-Enabled Drug Discovery. The panel will take place virtually on Friday, April 16, at 10:00 a.m. ET.